Key result
Activation of TLR7 protected against sepsis-induced cardiac dysfunction by promoting the cAMP-PKA-PLN pathway and restoring Ca2+ handling in a mouse model of septic cardiomyopathy.
Why the study?
The precise role and mechanism of Toll-like receptor 7 in septic cardiomyopathy remain unknown.
Does TLR7 activation improve cardiac systolic dysfunction in a preclinical model of septic cardiomyopathy?
Does TLR7 activation improve cardiac systolic dysfunction in a preclinical model of septic cardiomyopathy?
Activation of TLR7 protects against sepsis-induced cardiac dysfunction by promoting the cAMP-PKA-PLN pathway, highlighting a potential novel therapeutic target for septic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
TLR7 activation merits exploration as a therapy for septic cardiomyopathy; hypothesis-generating in mice, human trials required.
Background As a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanism of TLR7 in septic cardiomyopathy remain unknown. This study aims to determine the role of TLR7 in cardiac dysfunction during sepsis and explore the mechanism of TLR7 in septic cardiomyopathy. Methods We generated a mouse model of septic cardiomyopathy by challenging with lipopolysaccharide (LPS). TLR7‐knockout (TLR7−/−), wild‐type (WT) mice, cardiac‐specific TLR7‐transgenic (cTG‐TLR7) overexpression, and littermates WT (LWT) mice were subjected to septic model. Additionally, to verify the role and mechanism of TLR7 in vitro, we transfected neonatal rat ventricular myocytes (NRVMs) with Ad‐TLR7 and TLR7 siRNA before LPS administration. The effects of TLR7 were assessed by Ca2+ imaging, western blotting, immunostaining, and quantitative real‐time polymerase chain reaction (qPCR). Results We found that TLR7 knockout markedly exacerbated sepsis‐induced systolic dysfunction. Moreover, cardiomyocytes isolated from TLR7−/− mice displayed weaker Ca2+ handling than that in WT mice in response to LPS. Conversely, TLR7 overexpression alleviated LPS‐induced systolic dysfunction, and loxoribine (TLR7‐specific agonist) improved LPS‐induced cardiac dysfunction. Mechanistically, these optimized effects were associated with enhanced the adenosine (cAMP)‐protein kinase A (PKA) pathway, which upregulated phosphorylate‐phospholamban (p‐PLN) (Ser16) and promoted sarco/endoplasmic reticulum Ca2+ ATPase (Serca) and Ryanodine Receptor 2 (RyR2) expression in the sarcoplasmic reticulum (SR), and ultimately restored Ca2+ handling in response to sepsis. While improved Ca2+ handling was abrogated after H89 (a specific PKA inhibitor) pretreatment in cardiomyocytes isolated from cTG‐TLR7 mice. Consistently, TLR7 overexpression improved LPS‐induced Ca2+‐handling decrement in NRVMs. Nevertheless, TLR7 knockdown showed a deteriorative phenotype. Conclusions Our data demonstrated that activation of TLR7 protected against sepsis‐induced cardiac dysfunction through promoting cAMP‐PKA‐PLN pathway, and we revealed that TLR7 might be a novel therapeutic target to block the septic cardiomyopathy and support systolic function during sepsis.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2021) studied Septic cardiomyopathy. TLR7 activation or overexpression vs. TLR7 knockout or wild-type was evaluated on Cardiac dysfunction and Ca2+ handling. Activation of TLR7 protected against sepsis-induced cardiac dysfunction by promoting the cAMP-PKA-PLN pathway and restoring Ca2+ handling in a mouse model of septic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: